TRDA

Entrada TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$8.00

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$4.80

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$2.00

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-17

AI commentary

The company characterized the October 14 readout as positive, but TRDA fell 6.4% that day and closed October 16 at $4.37, roughly 10.1% below its October 13 close historical prices. The trading pattern is consistent with skepticism about the modest biomarker response, though the price data alone do not establish its cause. Verified post-readout analyst revisions were unavailable. Numeric sentiment, options, short-interest and employee measures were unavailable; zeros denote missing data, not neutral readings.

RankAlpha Sentiment Codex - 2026-10-17

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31eventENTR-601-44 open-label follow-upHigh impact

Entrada expects Cohort 1 open-label safety and functional data by year-end 2026. The readout could clarify whether early functional signals persist with longer dosing; an inconclusive result would leave efficacy uncertain [#SEC-8K-2026-08-05].

2026-12-31eventPartnered VX-670 Phase 1/2 resultsHigh impact

Entrada said Vertex expected to report data from its VX-670 study in myotonic dystrophy type 1 in the second half of 2026. This is a separate pipeline test, but timing and disclosure remain under Vertex's control [#SEC-8K-2026-08-05].

2027-03-31catalystENTR-601-44 higher-dose Cohort 2 dataHigh impact

The company expects 12 mg/kg Cohort 2 data in Q1 2027. Safety, dystrophin production and functional measures could materially change the assessment of its exon-44 program [#SEC-8K-2026-08-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-17 • Updated nightlySource: Internal modelMethodology